Related references
Note: Only part of the references are listed.Imaging and photodynamic therapy of prostate cancer using a theranostic PSMA-targeting ligand
Yvonne H. W. Derks et al.
EUROPEAN JOURNAL OF NUCLEAR MEDICINE AND MOLECULAR IMAGING (2023)
Eligibility for 177Lu-PSMA Therapy Depends on the Choice of Companion Diagnostic Tracer: A Comparison of 68Ga-PSMA-11 and 99mTc-MIP-1404 in Metastatic Castration-Resistant Prostate Cancer
Gary J. R. Cook et al.
JOURNAL OF NUCLEAR MEDICINE (2023)
A Single-Arm, Low-Dose, Prospective Study of 177 Lu-EB-PSMA Radioligand Therapy in Patients with Metastatic Castration-Resistant Prostate Cancer
Guochang Wang et al.
JOURNAL OF NUCLEAR MEDICINE (2023)
EANM dosimetry committee recommendations for dosimetry of 177Lu-labelled somatostatin-receptor- and PSMA-targeting ligands
Katarina Sjogreen Gleisner et al.
EUROPEAN JOURNAL OF NUCLEAR MEDICINE AND MOLECULAR IMAGING (2022)
Outcome of Patients with PSMA PET/CT Screen Failure by VISION Criteria and Treated with 177Lu-PSMA Therapy: A Multicenter Retrospective Analysis
Masatoshi Hotta et al.
JOURNAL OF NUCLEAR MEDICINE (2022)
PRINCE: Phase I trial of 177Lu-PSMA-617 in combination with pembrolizumab in patients with metastatic castration-resistant prostate cancer (mCRPC).
Shahneen Sandhu et al.
JOURNAL OF CLINICAL ONCOLOGY (2022)
Boron Vehiculating Nanosystems for Neutron Capture Therapy in Cancer Treatment
Giorgia Ailuno et al.
CELLS (2022)
What a difference a methylene makes: replacing Glu with Asp or Aad in the Lys-urea-Glu pharmacophore of PSMA-targeting radioligands to reduce kidney and salivary gland uptake
Hsiou-Ting Kuo et al.
THERANOSTICS (2022)
Therapeutic Efficacy of a Bivalent Inhibitor of Prostate-Specific Membrane Antigen Labeled with 67Cu
Lachlan E. McInnes et al.
JOURNAL OF NUCLEAR MEDICINE (2021)
A simple strategy to reduce the salivary gland and kidney uptake of PSMA-targeting small molecule radiopharmaceuticals
Teja Muralidhar Kalidindi et al.
EUROPEAN JOURNAL OF NUCLEAR MEDICINE AND MOLECULAR IMAGING (2021)
Synthesis and preclinical evaluation of an Al18F radiofluorinated bivalent PSMA ligand
Yong Huang et al.
EUROPEAN JOURNAL OF MEDICINAL CHEMISTRY (2021)
UpFrontPSMA: a randomized phase 2 study of sequential 177Lu-PSMA-617 and docetaxel vs docetaxel in metastatic hormone-naive prostate cancer (clinical trial protocol)
Nattakorn Dhiantravan et al.
BJU INTERNATIONAL (2021)
Global cancer statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries
Hyuna Sung et al.
CA-A CANCER JOURNAL FOR CLINICIANS (2021)
[177Lu]Lu-PSMA-617 versus cabazitaxel in patients with metastatic castration-resistant prostate cancer (TheraP): a randomised, open-label, phase 2 trial
Michael S. Hofman et al.
LANCET (2021)
Prostate-Specific Membrane Antigen Uptake and Survival in Metastatic Castration-Resistant Prostate Cancer
Panagiotis J. Vlachostergios et al.
FRONTIERS IN ONCOLOGY (2021)
Towards Targeted Alpha Therapy with Actinium-225: Chelators for Mild Condition Radiolabeling and Targeting PSMA-A Proof of Concept Study
Falco Reissig et al.
CANCERS (2021)
Efficacy and Safety of [225Ac]Ac-PSMA-617 Augmented [177Lu]Lu-PSMA-617 Radioligand Therapy in Patients with Highly Advanced mCRPC with Poor Prognosis
Florian Rosar et al.
PHARMACEUTICS (2021)
Clinical Trial Protocol for LuTectomy: A Single-arm Study of the Dosimetry, Safety, and Potential Benefit of 177Lu-PSMA-617 Prior to Prostatectomy
Nattakorn Dhiantravan et al.
EUROPEAN UROLOGY FOCUS (2021)
177Lu-PSMA-RLT of metastatic castration-resistant prostate cancer: limitations and improvements
Jianpeng Cao et al.
ANNALS OF NUCLEAR MEDICINE (2021)
ENZA-p trial protocol: a randomized phase II trial using prostate-specific membrane antigen as a therapeutic target and prognostic indicator in men with metastatic castration-resistant prostate cancer treated with enzalutamide (ANZUP 1901)
Louise Emmett et al.
BJU INTERNATIONAL (2021)
IEDDA: An Attractive Bioorthogonal Reaction for Biomedical Applications
Maryana Handula et al.
MOLECULES (2021)
Lutetium-177-PSMA-617 for Metastatic Castration-Resistant Prostate Cancer
Oliver Sartor et al.
NEW ENGLAND JOURNAL OF MEDICINE (2021)
Combined 177Lu-PSMA-617 PRLT and abiraterone acetate versus 177Lu-PSMA-617 PRLT monotherapy in metastatic castration-resistant prostate cancer: An observational study comparing the response and durability
Sonam Suman et al.
PROSTATE (2021)
Design of PSMA ligands with modifications at the inhibitor part: an approach to reduce the salivary gland uptake of radiolabeled PSMA inhibitors?
Veronika Barbara Felber et al.
EJNMMI RADIOPHARMACY AND CHEMISTRY (2021)
SQ3370 Activates Cytotoxic Drug via Click Chemistry at Tumor and Elicits Sustained Responses in Injected and Non-Injected Lesions
Sangeetha Srinivasan et al.
ADVANCED THERAPEUTICS (2021)
Photosensitizer-based multimodal PSMA-targeting ligands for intraoperative detection of prostate cancer
Yvonne H. W. Derks et al.
THERANOSTICS (2021)
225Ac-PSMA-617/177Lu-PSMA-617 tandem therapy of metastatic castration-resistant prostate cancer: pilot experience
Fadi Khreish et al.
EUROPEAN JOURNAL OF NUCLEAR MEDICINE AND MOLECULAR IMAGING (2020)
Lutetium-177-PSMA-I&T as metastases directed therapy in oligometastatic hormone sensitive prostate cancer, a randomized controlled trial
Bastiaan M. Prive et al.
BMC CANCER (2020)
Evaluation of Met-Val-Lys as a Renal Brush Border Enzyme-Cleavable Linker to Reduce Kidney Uptake of68Ga-Labeled DOTA-Conjugated Peptides and Peptidomimetics
Shreya Bendre et al.
MOLECULES (2020)
Novel therapies are changing treatment paradigms in metastatic prostate cancer
Eric Powers et al.
JOURNAL OF HEMATOLOGY & ONCOLOGY (2020)
Radioligand Therapy With 177Lu-PSMA for Metastatic Castration-Resistant Prostate Cancer: A Systematic Review and Meta-Analysis
Madhav Prasad Yadav et al.
AMERICAN JOURNAL OF ROENTGENOLOGY (2019)
A Bivalent Inhibitor of Prostate Specific Membrane Antigen Radiolabeled with Copper-64 with High Tumor Uptake and Retention
Nicholas A. Zia et al.
ANGEWANDTE CHEMIE-INTERNATIONAL EDITION (2019)
The Future of PSMA-Targeted Radionuclide Therapy: An Overview of Recent Preclinical Research
Eline A. M. Ruigrok et al.
PHARMACEUTICS (2019)
A Flexible Synthesis of 68Ga-Labeled Carbonic Anhydrase IX (CAIX)-Targeted Molecules via CBT/1,2-Aminothiol Click Reaction
Kuo-Ting Chen et al.
MOLECULES (2019)
Poor Outcomes for Patients with Metastatic Castration-resistant Prostate Cancer with Low Prostate-specific Membrane Antigen (PSMA) Expression Deemed Ineligible for 177Lu-labelled PSMA Radioligand Therapy
Sue Ping Thang et al.
EUROPEAN UROLOGY ONCOLOGY (2019)
Preferential Cleavage of a Tripeptide Linkage by Enzymes on Renal Brush Border Membrane To Reduce Renal Radioactivity Levels of Radiolabeled Antibody Fragments
Chie Suzuki et al.
JOURNAL OF MEDICINAL CHEMISTRY (2018)
[177Lu]-PSMA-617 radionuclide treatment in patients with metastatic castration-resistant prostate cancer (LuPSMA trial): a single-centre, single-arm, phase 2 study
Michael S. Hofman et al.
LANCET ONCOLOGY (2018)
Gadolinium borate and iron oxide bioconjugates: Nanocomposites of next generation with multifunctional applications
Okan Icten et al.
MATERIALS SCIENCE AND ENGINEERING C-MATERIALS FOR BIOLOGICAL APPLICATIONS (2018)
Albumin-Binding PSMA Ligands: Optimization of the Tissue Distribution Profile
Martina Benesova et al.
MOLECULAR PHARMACEUTICS (2018)
Synthesis of Symmetrical Tetrameric Conjugates of the Radiolanthanide Chelator DOTPI for Application in Endoradiotherapy by Means of Click Chemistry
Alexander Wurzer et al.
FRONTIERS IN CHEMISTRY (2018)
Monosodium Glutamate Reduces Ga-68-PSMA-11 Uptake in Salivary Glands and Kidneys in a Preclinical Prostate Cancer Model
Etienne Rousseau et al.
JOURNAL OF NUCLEAR MEDICINE (2018)
Synthesis and in vitro and in vivo evaluation of urea-based PSMA inhibitors with increased lipophilicity
Martina Wirtz et al.
EJNMMI RESEARCH (2018)
Glu-Ureido-Based Inhibitors of Prostate-Specific Membrane Antigen: Lessons Learned During the Development of a Novel Class of Low-Molecular-Weight Theranostic Radiotracers
Klaus Kopka et al.
JOURNAL OF NUCLEAR MEDICINE (2017)
Substitution determination of Fmoc-substituted resins at different wavelengths
Stefan Eissler et al.
JOURNAL OF PEPTIDE SCIENCE (2017)
Improving the Imaging Contrast of 68Ga-PSMA-11 by Targeted Linker Design: Charged Spacer Moieties Enhance the Pharmacokinetic Properties
Ann-Christin Baranski et al.
BIOCONJUGATE CHEMISTRY (2017)
Lutetium 177 PSMA radionuclide therapy for men with prostate cancer: a review of the current literature and discussion of practical aspects of therapy
Louise Emmett et al.
JOURNAL OF MEDICAL RADIATION SCIENCES (2017)
Linker Modification Strategies To Control the Prostate-Specific Membrane Antigen (PSMA)-Targeting and Pharmacokinetic Properties of DOTA-Conjugated PSMA Inhibitors
Martina Benesova et al.
JOURNAL OF MEDICINAL CHEMISTRY (2016)
PSMA-Targeted Radionuclide Therapy of Metastatic Castration-Resistant Prostate Cancer with 177Lu-Labeled PSMA-617
Clemens Kratochwil et al.
JOURNAL OF NUCLEAR MEDICINE (2016)
Towards Personalized Treatment of Prostate Cancer: PSMA I&T, a Promising Prostate-Specific Membrane Antigen-Targeted Theranostic Agent
Kristell L. S. Chatalic et al.
THERANOSTICS (2016)
Design of Internalizing PSMA-specific Glu-ureido-based Radiotherapeuticals
Till Wuestemann et al.
THERANOSTICS (2016)
PMPA for Nephroprotection in PSMA-Targeted Radionuclide Therapy of Prostate Cancer
Clemens Kratochwil et al.
JOURNAL OF NUCLEAR MEDICINE (2015)
Diabody Pretargeting with Click Chemistry In Vivo
Sander M. J. van Duijnhoven et al.
JOURNAL OF NUCLEAR MEDICINE (2015)
Preclinical Evaluation of a Tailor-Made DOTA-Conjugated PSMA Inhibitor with Optimized Linker Moiety for Imaging and Endoradiotherapy of Prostate Cancer
Martina Benesova et al.
JOURNAL OF NUCLEAR MEDICINE (2015)
Peptide/Protein Stapling and Unstapling: Introduction of s-Tetrazine, Photochemical Release, and Regeneration of the Peptide/Protein
Stephen P. Brown et al.
JOURNAL OF THE AMERICAN CHEMICAL SOCIETY (2015)
A Modular Strategy to Prepare Multivalent Inhibitors of Prostate-Specific Membrane Antigen (PSMA)
Sangeeta Ray Banerjee et al.
Oncotarget (2015)
Determination of peptide content and purity of DOTA-peptides by metal ion titration and UPLC: an alternative method to monitor quality of DOTA-peptides
Wouter A. P. Breeman et al.
JOURNAL OF RADIOANALYTICAL AND NUCLEAR CHEMISTRY (2014)
Improving the biodistribution of PSMA-targeting tracers with a highly negatively charged linker
Steve S. Huang et al.
PROSTATE (2014)
Synthesis and preclinical evaluation of DOTAGA-conjugated PSMA ligands for functional imaging and endoradiotherapy of prostate cancer
Martina Weineisen et al.
EJNMMI RESEARCH (2014)
trans-Cyclooctene - a stable, voracious dienophile for bioorthogonal labeling
Ramajeyam Selvaraj et al.
CURRENT OPINION IN CHEMICAL BIOLOGY (2013)
A dimerized urea-based inhibitor of the prostate-specific membrane antigen for Ga-68-PET imaging of prostate cancer
Martin Schaefer et al.
EJNMMI RESEARCH (2012)
A Remote Arene-Binding Site on Prostate Specific Membrane Antigen Revealed by Antibody-Recruiting Small Molecules
Andrew X. Zhang et al.
JOURNAL OF THE AMERICAN CHEMICAL SOCIETY (2010)
Preclinical Evaluation of Novel Glutamate-Urea-Lysine Analogues That Target Prostate-Specific Membrane Antigen as Molecular Imaging Pharmaceuticals for Prostate Cancer
Shawn M. Hillier et al.
CANCER RESEARCH (2009)
A Series of Halogenated Heterodimeric Inhibitors of Prostate Specific Membrane Antigen (PSMA) as Radiolabeled Probes for Targeting Prostate Cancer
K. P. Maresca et al.
JOURNAL OF MEDICINAL CHEMISTRY (2009)
Design, Synthesis, and Preclinical Evaluation of Prostate-Specific Membrane Antigen Targeted 99mTc-Radioimaging Agents
Sumith A. Kularatne et al.
MOLECULAR PHARMACEUTICS (2009)
Structural insight into the pharmacophore pocket of human glutamate carboxypeptidase II
Cyril Barinka et al.
JOURNAL OF MEDICINAL CHEMISTRY (2007)
Structure of glutamate carboxypeptidase II, a drug target in neuronal damage and prostate cancer
JR Mesters et al.
EMBO JOURNAL (2006)
Design of remarkably simple, yet potent urea-based inhibitors of glutamate carboxypeptidase II (NAALADase)
AP Kozikowski et al.
JOURNAL OF MEDICINAL CHEMISTRY (2001)
Share Paper
